Beta version (currently under testing). If you would like to visit the old website, click here.

Cristian Munteanu, Dr.

Cristian Munteanu
Group: Bioinformatics & Structural Biochemistry
Department: Bioinformatics & Structural Biochemistry

Research Scientist

Biography

ACADEMIC CAREER
2016 – present: Research Scientist (CS) at the Institute of Biochemistry of the
Romanian Academy (IBRA)
2014 – 2016: Research Assistant at IBRA

EDUCATION AND TRAINING
2011 – 2016: Ph.D. in Biology at Institute of Biochemistry of the Romanian
Academy (IBRA) with the thesis title: “Insights into functional
interaction proteomics of endoplasmic reticulum associated
degradation (ERAD) and antigen presentation in melanoma using
mass spectrometry”, Coordinators: Dr. Andrei Jose Petrescu/Dr.
Niculina Mitrea (University of Medicine and Pharmacy Carol Davila,
Bucharest)
2011 – 2014: Resident Pharmacist in Pharmaceutical Laboratory at University of
Medicine and Pharmacy (UMF) Carol Davila, Bucharest, Romania
(Accredited Postgraduate Medical Specialization by the Ministry of
Health from Romania)
2010 – 2012: MSc in Biological Chemistry at Normal Superior School of
Bucharest (NSSB) - IBRA with the thesis title: “Expression and
purification of the antimicrobial peptide Cecropin P1 in Escherichia
Coli”
2005 – 2010: B.Sc. and M.Sc in Pharmacy at UMF Carol Davila (Bucharest,
Romania) with the thesis title: “HPLC and molecular modeling
stability evaluation of inclusion complexes between repaglinide and
beta-cyclodextrin”

Papers

Year
View all papers

Grants

Mass spectrometry based investigation of the oxidative stress as a potential key-player in the immunobiology of melanoma 02/05/2018 - 30/04/2020
Acronym: IMUNOPEP
Project director: Cristian Munteanu

A promising approach of the therapeutic strategy in melanoma is immunotherapy. One of the most promising melanoma antigens is tyrosinase, which was frequently found as overexpressed in melanomas. It wash shown that this protein undergoes unproductive folding in the endoplasmic reticulum (ER) leading to the selection of the incorrectly folded molecules for degradation via the ubiquitin proteasome system. The current project aims to obtain epitopes with potential increased clinical outcome.

Role of TG2 in cancer tumor microenvironment for guiding metastasis prevention therapeutic approaches 2020-2022
Acronym: TG2TARGET
Budget: 431,900 RON
Project director: Livia Sima

The overall goal of the current project is to understand the impact of tissue transglutaminase (TG2) targeting in the context of ovarian cancer (OC) tumor microenvironment (TME). Our aproach is aimed at testing the hypothesis that interventions in targeting TG2 in the OC TME will disrupt pro-tumorigenic signaling cross-talk within tumors.

Context-dependent therapeutic targeting of ovarian cancer metastasis using TG2 small molecule inhibitors 2020-2022
Acronym: TG2THERAPY
Budget: 600,000 RON
Project director: Livia Sima

The principal goal of this project is the development of a new class of small molecule inhibitors (SMIs) targeting TG2-FN interaction, which is currently in the phase of lead optimization, translatable to clinical use for prevention of ovarian cancer dissemination, either alone or in combinations.